跳至主要内容
临床试验/NCT04624698
NCT04624698进行中(未招募)不适用

iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study

Glaukos Corporation6 个研究点 分布在 1 个国家目标入组 358 人开始时间: 2020年9月22日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
358
试验地点
6
主要终点
iStent inject placement and stability

研究概览

简要总结

Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.

详细描述

To evaluate the rate of clinically relevant complications associated with iStent inject placement and stability, as determined at 36 months in the postmarket setting.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥ 22 years of age
  • Mild to moderate primary open-angle glaucoma
  • Scheduled to undergo cataract surgery
  • Able and willing to attend scheduled follow-up exams for three years postoperatively
  • Able and willing to provide written informed consent on the IRB approved Informed Consent Form
  • Operative Inclusion Criterion:
  • Successful, uncomplicated cataract surgery

排除标准

  • Angle closure glaucoma
  • Traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle
  • Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure

结局指标

主要结局

iStent inject placement and stability

时间窗: 36 Months

The rate of clinically relevant complications associated with iStent inject placement and stability

次要结局

  • Sight-threatening adverse events(36 Months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验